Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Fig. 2

Intervention and assessment schedule for the MEDAL trial according to the Recommendations for Interventional Trials (SPIRIT). Patients will visit the hospital every 4 weeks until about 24 weeks after radiotherapy, and then every 3 months for the next 2 years to collect data. *according to the Common Toxicity Criteria for Adverse Events (CTCAE v 5.0), **questionnaires: FACT-P, EQ-5D. PSA Prostate-specific antigen, QOL Quality of life

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us